不同直接抗病毒药物方案对基因1b型慢性丙型肝炎及代偿期丙型肝炎肝硬化临床结局的影响

侯艺辉; 刘腾飞; 赵晓青; 张缭云

doi:10.3969/j.issn.1001-5256.2020.01.019

不同直接抗病毒药物方案对基因1b型慢性丙型肝炎及代偿期丙型肝炎肝硬化临床结局的影响

DOI: 10.3969/j.issn.1001-5256.2020.01.019

1. 山西医科大学
2. 山西医科大学第一医院感染病科

详细信息

中图分类号: R512.63;R575.2
计量
- 文章访问数: 1353
- HTML全文浏览量: 64
- PDF下载量: 240
- 被引次数: 0
出版历程
- 收稿日期: 2019-08-18
- 出版日期: 2020-01-20

Effect of different direct-acting antivirals on the clinical outcome of genotype 1b chronic hepatitis C and compensated hepatitis C cirrhosis

Shanxi Medical University

摘要

摘要: 目的探讨不同直接抗病毒药物（DAAs）对基因1b型慢性丙型肝炎（CHC）及丙型肝炎代偿期肝硬化（CLC）临床结局的影响。方法以2018年1月-2018年12月就诊于山西医科大学第一医院感染科门诊的115例基因型1b型CHC（n=91）及CLC（n=24）患者为研究对象。所有患者根据病情均采用DAAs抗病毒治疗,CHC患者中28例采用索磷布韦联合维帕他韦方案,21例采用艾尔巴韦格拉瑞韦片方案,16例采用奥比帕利联合达塞布韦方案,13例采用索磷布韦联合达拉他韦方案,13例采用索磷布韦联合利巴韦林方案; CLC患者中15例采用索磷布韦联合维帕他韦方案,4例采用艾尔巴韦格拉瑞韦片方案,5例采用索磷布韦联合达拉他韦方案。分析2组患者的肝功能复常率及病毒学应答率,并观察药物的不良反应。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验。结果 90. 4%的患者在治疗1周时获得超快速病毒学应答,98. 2%的患者在治疗4周时获得快速病毒学应答,100%的患者在治疗12周时获得完全早期病毒学应答,100%的患者在治疗结束后12周获得持续病毒学应答;不同抗病毒治疗方案在治疗1周、4周时HCV RN...
- 丙型肝炎,慢性 /
- 抗病毒药 /
- 治疗结果 /
- 持续病毒学应答
Abstract: Objective To investigate the effect of different direct-acting antivirals(DAAs) on the clinical outcome of genotype 1 b chronic hepatitis C(CHC) and compensated liver cirrhosis(CLC). Methods A total of 115 patients with genotype 1 b CHC and CLC who were treated in Department of Infectious Diseases in The First Hospital of Shanxi Medical University from January to December,2018 were enrolled as subjects,among whom there were 91 patients with CHC and 24 patients with CLC. All patients were given antiviral therapy with DAAs according to their conditions. Among the patients with CHC,28 were treated with sofosbuvir and velpatasvir(SOF + VEL),21 were treated with elbasvir and grazoprevir tablets(EBR + GZR),16 were treated with ombitasvir and dasabuvir(OBV + DSV),13 were treated with sofosbuvir and daclatasvir(SOF + DCV),and 13 were treated with sofosbuvir and ribavirin(SOF + RBV); among the 24 patients with CLC,15 were treated with sofosbuvir and velpatasvir(SOF + VEL),4 were treated with elbasvir and grazoprevir tablets(EBR + GZR),and5 were treated with sofosbuvir and daclatasvir(SOF + DCV). The two groups were compared in terms of normalization rate of liver function and virologic response rate,and adverse drug reactions were observed. The t-test was used for comparison of continuous data between groups,and the chi-square test was used for comparison of categorical data between groups. Results Of all patients,90. 4% achieved super-rapid virologic response at 1 week of treatment,98. 2% achieved rapid virologic response at week 4 of treatment,100% achieved complete early virologic response at week 12 of treatment,and 100% achieved sustained virologic response at week 12 after the end of treatment.There was no significant difference in HCV RNA seroconversion rate between the patients receiving different antiviral treatment regimens at weeks 1 and 4 of treatment(χ2= 2. 83 and 0. 07,P > 0. 05). All antiviral treatment regimens significantly improved the liver function of patients,and there was no significant difference in clinical outcome between different groups(χ2= 0. 83 and 1. 23,P > 0. 05). Both groups had no significant increase or reduction in renal function parameters after 12 weeks of the treatment with DAAs(t = 1. 32 and 0. 56,P >0. 05). There was a low incidence rate of adverse events,with two cases of nausea(1. 74%) and one case each of dizziness,palpitation,rash,and hemolysis(0. 87%). Conclusion In patients with genotype 1 b disease,DAA antiviral regimens selected based on their conditions can achieve good virologic response rate,with significant improvement in liver function and a low incidence rate of adverse events.
- chronic hepatitis C /
- antiviral agents /
- treatment outcome /
- sustained virologic response

HTML全文

参考文献(14)

[1] HOU F,QI HY,YIN CH. Progress in drug treatment of chronic hepatitis C[J]. Chin J Med,2017,52(4):1-3.(in Chinese)侯斐，齐海宇，阴赪宏．慢性丙型肝炎的药物治疗进展[J]．中国医刊，2017,52(4):1-3.

[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1961-1979.

[3] KOHLI A,ALSHATI A,GEORGIE F,et al. Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease[J]. Therap Adv Gastroenterol,2016,9(6):887-897.

[4] WANG YB,XIE W. Chronic hepatitis C treatment:Hot spots,difficulties and problems that need to be solved[J]. Chin Clin Dr,2019,47(3):253-254.(in Chinese)王艳斌，谢雯．慢性丙型肝炎治疗:热点、难点及亟须解决的问题[J]．中国临床医生杂志，2019,47(3):253-254.

[5] HONER Z,MAASOUMY B,MARRA F,et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort[J]. Clin Infect Dis,2016,62(5):561-567.

[6] CHEN JH,ZENG Z,ZHANG XX. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting[J]. World J Gastroenterol,2017,23(22):4072-4079.

[7] ZHUANG LW,JI SB,ZHANG Y,et al. Efficacy and safety of Sofosbuvir combined with Velpatasvir in treatment of chronic hepatitis C and hepatitis C related liver cirrhosis patients with genotype 1~6:A Meta-analysis[J/CD]. Chin J Liver Dis:Electr Version,2019,11(2):30-36.(in Chinese)庄立伟，纪世博，张雨，等．Sofosbuvir联合Velpatasvir治疗1~6基因型慢性丙型肝炎和丙型肝炎肝硬化患者疗效及安全性Meta分析[J/CD]．中国肝脏病杂志:电子版，2019,11(2):30-36.

[8] WANG JJ,WANG YB. Progress in direct antiviral drugs for hepatitis C virus[J]. Chin Clin Dr,2019,47(3):258-261.(in Chinese)王京京，王艳斌．丙型病毒性肝炎直接抗病毒药物研究进展[J]．中国临床医生杂志，2019,47(3):258-261.

[9] YIN YX,MENG ZQ,LI XG,et al. Clinical effect of direct-acting antiviral agents for hepatitis C[J]. Chin Hepatol,2018,23(9):772-774.(in Chinese)尹艳霞，孟子强，李晓光．直接抗病毒药物治疗慢性丙型肝炎的临床疗效观察[J]．肝脏，2018,23(9):772-774.

[10] AN ZY,SHENG QJ,DING Y,et al. Early efficacy and safety of direct-acting antivirals agents for the treatment of cirrhotic patients with hepatitis C[J]. Infect Dis Info,2016,29(2):81-84,96.(in Chinese)安子英，盛秋菊，丁洋，等．直接抗病毒药物治疗丙型肝炎肝硬化早期抗病毒疗效及安全性临床实践研究[J]．传染病信息，2016,29(2):81-84,96.

[11] JI F,WANG W,DANG S,et al. Outcomes after sofobuvircontaining regimes for hepatitis C virus in patients with decompensated cirrhosis:A real-world study[J]. Infect Agent Cancer,2017,12:48.

[12] JI D,CHEN GF,WANG C,et al. Twelve-week ribavirinfree direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients[J]. Hepatol Int,2016,10(5):798-798.

[13] YANG Y,DANG SS. Safety of direct antiviral agents for treatment of hepatitis C virus infection[J]. World Chin J Dig,2017,25(8):659-669.(in Chinese)杨颖，党双锁．丙型肝炎直接抗病毒药物安全性应用进展[J]．世界华人消化杂志，2017,25(8):659-669.

[14] BUNNELL KL,VIBHAKAR S,GLOWACKI RC,et al. Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection[J]. Pharmacotherapy,2016,36(9):e148-e153.

施引文献

资源附件(0)

访问统计